Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PIK3CA H1047R |
| Therapy | OKI-219 |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PIK3CA H1047R | Advanced Solid Tumor | predicted - sensitive | OKI-219 | Preclinical - Pdx | Actionable | In a preclinical study, OKI-219 decreased Akt phosphorylation and proliferation in tumor cell lines harboring PIK3CA H1047R in culture and inhibited tumor growth in cell line xenograft models and patient-derived xenograft (PDX) models (Mol Cancer Ther (2023) 22 (12_Supplement): B163). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Abstract B163: Discovery and characterization of OKI-219, an orally bioavailable H1047R-mutant-selective inhibitor of PI3Ka | Full reference... |